Cerity Partners
RXRX icon

Cerity Partners’s Recursion Pharmaceuticals RXRX Stock Holding History

Cerity Partners’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$196K Sell
63,919
-6,362
-9% -$24.6K ﹤0.01% 2888
2025
Q4 		$287K Buy
70,281
+8,732
+14% +$43.3K ﹤0.01% 2435
2025
Q3 		$300K Buy
61,549
+795
+1% +$4.17K ﹤0.01% 2282
2025
Q2 		$307K Sell
60,754
-1,937
-3% -$9.52K ﹤0.01% 2145
2025
Q1 		$332K Buy
+62,691
New +$457K ﹤0.01% 1972

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Cerity Partners's RXRX Position: Q1 2026 in Review

Cerity Partners reduced its Recursion Pharmaceuticals (RXRX) stake by 9.1% in Q1 2026, selling an estimated $24.6K and leaving 63,919 shares worth $196K. The position accounts for ﹤0.01% of the portfolio, ranked #2888.

Cerity Partners first reported a position in RXRX in Q1 2025 and has held it in 5 quarters since. The position peaked at $332K in Q1 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Cerity Partners held 63,919 shares of Recursion Pharmaceuticals worth $196K as of Q1 2026.
  • Cerity Partners sold 6,362 Recursion Pharmaceuticals shares in Q1 2026, an estimated $24.6K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Cerity Partners's portfolio in Q1 2026, its #2888 holding.
  • Cerity Partners first reported a position in Recursion Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • Cerity Partners's Recursion Pharmaceuticals position peaked at $332K in Q1 2025.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Cerity Partners's 13F filing for Q1 2026, filed 15 May 2026.